

Provisional Notice of the Interim Result

of the public tender offer by

Samsung Peptide AG, Zug, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

PolyPeptide Group AG, Baar, Switzerland

1. The Offer

On August 31, 2026, Samsung Peptide AG (**Offeror** or **Samsung Peptide**) published the offer prospectus (**Offer Prospectus**) for its public tender offer according to articles 125 et seq. FMIA (**Offer**) for all publicly held registered shares of PolyPeptide Group AG (**PolyPeptide** or **Company**) with a nominal value of CHF 0.01 each (each a **PolyPeptide Share**, all together **PolyPeptide Shares**). The offer price for each PolyPeptide Share is CHF 44.31 net in cash (**Offer Price**) (as further described in the Offer Prospectus).

The Offer relates to a maximum of 33,016,411 PolyPeptide Shares, as further detailed in section B.2 (*Object of the Offer*) of the Offer Prospectus.

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

2. Provisional Interim Result

As of the end of the Main Offer Period on October 12, 2026, 4:00 p.m. Swiss time, and based on preliminary figures, the participation of the Offeror and the persons acting in concert with the Offeror amounts to 29,123,892 PolyPeptide Shares in aggregate, corresponding to 87.92% of the issued share capital and voting rights of PolyPeptide (*participation rate*). 29,014,418 PolyPeptide Shares were tendered into the Offer until the end of the Main Offer Period, corresponding to 87.88% of all PolyPeptide Shares to which the Offer relates (*success rate*). The Offeror and the persons acting in concert with the Offeror (excluding PolyPeptide and its direct and indirect Subsidiaries as well as the Principal Shareholder and all companies directly or indirectly controlled by the Principal Shareholder) have, between July 20, 2026 and the end of the Main Offer Period, acquired a total of 17 PolyPeptide Shares on- or off-exchange.

The following overview summarizes the interim result based on preliminary figures:

	Number of PolyPeptide Shares	In % of voting rights/share capital (participation rate)	In % of PolyPeptide Shares to which the Offer relates (success rate)
PolyPeptide Shares tendered into the Offer	29,014,418	87.59%	87.88%
PolyPeptide Shares held by the Offeror and the persons acting in concert with the Offeror at the end of the Main Offer Period	109,474	0.33%	
Provisional Interim Result	29,123,892	87.92%	

3. Definitive Notice of the Interim Result

The interim result announced in this notice is preliminary. The definitive notice of the interim result is expected to be published on October 16, 2026.

4. Offer Conditions

Subject to confirmation of the preliminary numbers in the definitive notice of the interim result, the Offer Condition pursuant to section B.7.1(a) (*Minimum Acceptance Rate*) of the Offer Prospectus has been satisfied. In addition, the Offer Condition pursuant to section B.7.1(d) (*No Material Adverse Effect*) of the Offer Prospectus has also been satisfied.

The Offer remains subject to the Offer Conditions pursuant to section B.7.1 of the Offer Prospectus.

5. Additional Acceptance Period

If the Offer is declared successful (*zustande gekommen*) in the definitive notice of the interim result, the Additional Acceptance Period of ten (10) Trading Days for the subsequent acceptance of the Offer will commence on October 19, 2026 and end on October 30, 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (*Additional Acceptance Period*) of the Offer Prospectus.

6. Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus is available at the designated offer website of the Offeror (<https://samsungbiologics.com/offer>) and may also be obtained free of charge in German, French and English from UBS AG, Investment Bank, Swiss

Prospectus Switzerland, P.O. Box, CH-8098 Zurich, Switzerland (email: swiss-prospectus@ubs.com; telephone: +41 44 239 47 03).

	Swiss securities number	ISIN	Ticker symbol
PolyPeptide Shares not tendered (first trading line)	111 076 085	CH1110760852	PPGN
PolyPeptide Shares tendered (second trading line)	159 344 976	CH1593449767	PPGNE

Zug, October 13, 2026

Offer Manager: UBS AG, 8001 Zurich, Switzerland